Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole

Journal of Pharmaceutical Sciences

Volumn 87, Issue 12, 1998, Pages 1538-1541

  Khoo, Shui Mei ^a   Porter, Christopher J H ^a   Edwards, Glenn A ^b   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBUTYLHALOFANTRINE; HALOFANTRINE; KETOCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TRANSPORT; FOOD DRUG INTERACTION; INTESTINE CELL; LYMPHATIC SYSTEM; NONHUMAN;

EID: 0031798010     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980185w     Document Type: Article

References (17)

1. Bryson, H. M.; Goa, K. L. Halofantrine - A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992, 43, 236-258.
2. Milton, K. A.; Edwards, G.; Ward, S. A.; Orme, M. L'E.; Breckenridge, A. M. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br. J. Clin. Pharmacol. 1989, 28, 71-77.
3. Humberstone, A. J.; Porter, C. J. H.; Charman, W. N. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J. Pharm. Sci. 1996, 85, 525-529.
4. Monlun, E.; Le Metayer, P.; Szwandt, S.; Neau, D.; LongyBousier, M.; Horton, J.; Le Bras, M. Cardiac complications of Hf: A prospective study of 20 patients. Trans. R. Soc. Trop. Med. Hyg. 1995, 89, 430-433.
5. Karbwang, J.; Na Bangchang, K.; Bunnag, D.; Harinasuta, T.; Laothavorn, P. Cardiac effect of halofantrine. Lancet 1993, 342, 501.
6. Touze, J. E.; Bernard, J.; Keundjian, A.; Imbert, P.; Viguier, A.; Chaudet, H.; Doury, J. C. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Am. J. Trop. Med. Hyg. 1996, 54, 225-228.
7. Halliday, R. C.; Jones, B. C.; Smith, D. A.; Kitteringham, N. R.; Park, B. K. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br. J. Clin. Pharmacol. 1995, 40, 369-378.
8. Kivistö, K. T.; Bookjans, G.; Fromm, M. F.; Griese, E.-U.; Münzel, P.; Kroemer, H. K. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J. Clin. Pharmacol. 1996, 42, 387-389.
9. Wacher, y. J.; Salphati, L.; Benet, L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Del. Rev. 1996, 20, 99-112.
10. Maurice, M.; Pichard, L.; Daujat, M.; Fahre, L; Joyeux, H.; Domergue, J.; Maurel, P. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 1992, 6, 752-758.
11. Myre, S. A.; Schoeder, T. J.; Grund, V. R.; Wandstrat, T. L.; Nicely, P. G.; Pesce, A. J.; First, M. R. Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991, 43, 233-241.
12. Humberstone, A. J.; Currie, G. J.; Porter, C. J. H.; Scanlon, M. J.; Charman, W. N. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkafine conditions. J. Pharm. Biomed. Anal. 1995, 13, 265-272.
13. Krishna, S.; ter Kuile, F.; Supanaranond, W.; Pukrittayakamee, S.; Teja-Isavadharm, P.; Kyle, D.; White, N. J. Pharmacokinetics, efficacy and toxicity of patenterai halofantrine in uncomplicated malaria. Br. J. Clin. Pharmacol. 1993,36, 585-591.
14. Prueksaritanont, T.; Gorham, L. M.; Hochman, J. H.; Tran, L. O.; Vyas, K. P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. 1996, 24, 634-642.
15. Benêt, L. Z.; Wacher, V. J.; Benet, R. M. Use of essential oils to increase bioavailability of oral pharmaceutical compounds. US Patent 5,665,386.
16. Porter, C. J. H.; Charman, S. A.; Charman, W. N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J. Pharm. Sci. 1996, 85, 351-356.
17. Cowman, A. F.; Galatis, D.; Thompson, J. K. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdrl gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. 1994, 91, 1143-1147.